Announcements Trials
Browse Landscape

Phase

Phase 2 2Phase 2/3 1

Status

Unknown 1Recruiting 1Active not recruiting 1

Sponsor Class

OTHER 344INDUSTRY 298NIH 45NETWORK 6OTHER_GOV 3

Study Type

Interventional 3Observational 1

Sponsor

Cancer Type

Thoracic 1Gastrointestinal 1Breast 1

Conditions

Triple Negative Breast Neoplasms 1Small Cell Lung Cancer Recurrent 1Carcinoma, Hepatocellular 1

Interventions

Cisplatin 49Capecitabine 41apatinib 34Gemcitabine 33Oxaliplatin 32Cyclophosphamide 31Radiotherapy 29Paclitaxel 29Carboplatin 29tislelizumab 27Irinotecan 27Drug Therapy 27Fluorouracil 26Docetaxel 26Bevacizumab 23fludarabine 18Surgical Procedures, Operative 17Nivolumab 17pembrolizumab 16Exercise 16Metformin 15camrelizumab 14S 1 (combination) 14Radiation 14Pemetrexed 13Control Groups 12anlotinib 11Leucovorin 11toripalimab 10Vinorelbine 10

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
OTHER_GOV × Interventional × atezolizumab × Clear all
NCT03756298 2026-04-23

Efficacy and Safety of Atezolizumab Plus Capecitabine Adjuvant Therapy for Triple Receptor-Negative Breast Cancer

National Cancer Center, Korea

Phase 2 Active not recruiting
284 enrolled
Breast

Triple Negative Breast Neoplasms

NCT07293468 2026-04-09

BIIRTH

Tuen Mun Hospital

Phase 2/3 Recruiting
106 enrolled
Gastrointestinal

Carcinoma, Hepatocellular

NCT03262454 2022-04-06

Atezolizumab

National Cancer Center, Korea

Phase 2 Unknown
35 enrolled
Thoracic

Small Cell Lung Cancer Recurrent

Data powered by HemOnc (CC BY 4.0) Colophon âš¡